The US Department of Defense awarded Emergent BioSolutions Inc. with a contract worth up to $235.8 million to supply all branches of the US military with BioThrax (Anthrax Vaccine Adsorbed) for use as pre-exposure prophylaxis against anthrax disease.
Related Posts
Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics,…
The Potential Association Between Allostatic Load and Male Cancer Mortality
Image Credit: Adobe Stock Images/Krakenimages.com In the United States, the cancer incidence rate among men is 497 cases per 100,000…
Systech, Praxis Packaging Strike Track-and-Trace Partnership
Image Credit: Adobe Stock Images/VisualGeneration.com Systech, a provider of digital identification and traceability solutionsfor the pharma industry, was selected by…